Amgen kept at neutral by Merrill

Amgen Inc. was maintained at a neutral rating by Merrill Lynch analyst Eric Ende. The company, along with Abgenix Inc., submitted its Biologics License Application for Panitumumab in third-line colorectal cancer. Merrill believes the submission will get priority review, with approval possible in the third or fourth quarter of 2006. Full data including survival for the pivotal phase 3 European study will be presented April 3. Shares of the Thousand Oaks, Calif., biotechnology company were up 60 cents, or 0.83%, at $72.62 on volume of 7,387,326 shares versus the three-month running average of 10,552,500 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.